Pasireotide in the Personalized Treatment of Acromegaly

The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some months to be fully evaluated. Considering thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Puig-Domingo, Manel, Bernabéu, Ignacio, Picó, Antonio, Biagetti, Betina, Gil, Joan, Alvarez-Escolá, Cristina, Jordà, Mireia, Marques-Pamies, Montserrat, Soldevila, Berta, Gálvez, María-Angeles, Cámara, Rosa, Aller, Javier, Lamas, Cristina, Marazuela, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008639/
https://www.ncbi.nlm.nih.gov/pubmed/33796079
http://dx.doi.org/10.3389/fendo.2021.648411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008639/
https://www.ncbi.nlm.nih.gov/pubmed/33796079
http://dx.doi.org/10.3389/fendo.2021.648411

Ejemplares similares